EYEG - EyeGate names Brian Strem CEO proposes $7M Bayon deal

Delmaine Donson/E+ via Getty Images EyeGate Pharmaceuticals (EYEG) announces the appointment of Brian Strem as the company's president and chief executive officer. Additionally, EyeGate has entered a non-binding letter of intent to acquire privately held Bayon Therapeutics for a consideration of up to $7.1M. Further terms of the proposed transaction will be provided by upon EyeGate and Bayon entering into a definitive agreement for the transaction, the company said. Strem, who was the Co-Founder, Director and former Chief Executive Officer of Okogen, is a biotech executive and entrepreneur with a strong ophthalmology background. EyeGate shares up more than 11% post market.

For further details see:

EyeGate names Brian Strem CEO, proposes $7M Bayon deal